Navigation Links
NxStage Appoints New Member to Its Board of Directors and Announces Resignation of Board Member
Date:10/28/2008

LAWRENCE, Mass., Oct. 28 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the addition of Earl R. Lewis to the Company's Board of Directors and the resignation of Peter P. Phildius from the Board.

"I first want to thank Pete for the contributions he has made to the Company. I have benefited greatly from working closely with him over the last 10 years. We look forward to working with Earl and leveraging his extensive business experience," said Jeff Burbank, Chief Executive Officer of NxStage Medical. "His record of successes with high growth technology companies will be of significant value to us as we continue to expand our business."

Mr. Lewis is the current Chairman, President and CEO of Flir Systems Inc. (NYSE: FLIR), a manufacturer of thermal imaging and infrared camera systems. Previously, he served as CEO and President at Thermo Instrument Systems, Inc. He also served Thermo in various executive capacities, including President and Chief Operating Officer, CEO and President of Thermo Optek Corp., and President of Thermo Jarrell Ash Corp. Mr. Lewis is also a member of the board of directors for Harvard Bio Science and American DG Energy.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the contributions Mr. Lewis will make to NxStage's performance and operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements. Certain factors which may affect future operating results are detailed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the period ending June 30, 2008. In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

Contact:

Kristen K. Sheppard, Esq.

VP, Investor Relations

ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NxStage Announces Presentation of Data at the American Society of Nephrologys Renal Week 2008 Annual Meeting
2. NxStage Reports Second Quarter 2008 Financial Results
3. NxStage Announces $43 Million Private Placement of Equity Securities
4. NxStage Medical Reports First Quarter 2008 Results
5. NxStage Announces Supply Agreement With Kawasumi Laboratories for Blood Tubing Sets
6. Tsongas Visits Lawrence-based Medical Device Maker NxStage Medical, Inc.
7. Emil Paganini, MD, Joins NxStage(R) as Critical Care Medical Advisor
8. NxStage Medical Reports Fourth Quarter and Full Year 2007 Results
9. NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008
10. NxStage(R) Medical to Report Fourth Quarter & Full Year 2007 Financial Results on Tuesday, February 12th
11. NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... ... an inspirational story for those shackled by the chains of a broken life. “God ... and a woman of great faith and wisdom. She is a great motivational speaker. ... and raised in Vero Beach, Florida and has dedicated her life and ministry to letting ...
(Date:8/15/2017)... ... 2017 , ... The first study to report that overall survival was extended ... the team’s findings now published online ahead of print in the Journal of Clinical ... Marrow Transplant Program at Roswell Park Cancer Institute, was principal investigator for one of ...
(Date:8/15/2017)... , ... August 15, 2017 , ... Progressive Dental, a ... a spot on the 2017 Fast 50 list of Fastest Growing Companies in Tampa ... seven county area who has shown three consecutive years of growth. For this year’s ...
(Date:8/15/2017)... ... August 15, 2017 , ... Dr. Timothy ... patient’s periodontal disease . This information can be used to develop patient-specific ... , The two salivary diagnostic tests, named MyPerioPath® and MyPerioID® are offered by ...
(Date:8/15/2017)... ... August 15, 2017 , ... Rejuvenate ... of services. FDA-cleared CoolSculpting is the world’s most popular non-invasive fat reduction treatment, ... CoolSculpting can reduce fat cells in almost any area of the body, including ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 ... from continuing operations Second-quarter ... $110 million Second-quarter 2017 ... Second-quarter 2017 adjusted diluted ... percent to $0.93 Second-quarter ...
(Date:8/7/2017)... 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... ended June 30, 2017.  All comparisons, unless otherwise noted, are ... Second Quarter 2017 Highlights include: ... million, an increase of 3.5% Total prescriptions ... margin of 7.5% versus 7.6% Gross ...
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and other ... up healthcare costs and threatening outcomes, were problems taken ... and IVD industry that support them, met this week. ... researcher said that drugs of abuse, procalcitonin and acute ... at the organization,s 69th meeting in San ...
Breaking Medicine Technology: